about
Genomics and cancer drug resistance.International Survey of ALS Experts about Critical Questions for Assessing Patients with ALS.Dynamics of Expression of Drug Transporters: Methods for Appraisal.Young-onset rapidly progressive ALS associated with heterozygous FUS mutation.Brain white matter demyelinating lesions and amyotrophic lateral sclerosis in a patient with C9orf72 hexanucleotide repeat expansion.Plasma level of club-cell (CC-16) predicts outcome in amyotrophic lateral sclerosis.Sialorrhoea and reversals in ALS functional rating scale.Instability of mRNA expression signatures of drug transporters in chronic myeloid leukemia patients resistant to imatinib.Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction modelPhosphoneurofilament heavy chain and vascular endothelial growth factor as cerebrospinal fluid biomarkers for ALSContrast between extensive variation of 28S rDNA and stability of 5S rDNA and telomeric repeats in the diploid-polyploid Squalius alburnoides complex and in its maternal ancestor Squalius pyrenaicus (Teleostei, Cyprinidae)Cytogenetic analysis of Anaecypris hispanica and its relationship with the paternal ancestor of the diploid-polyploid Squalius alburnoides complexLack of correspondence between CMA 3 -, Ag-positive signals and 28S rDNA loci in two Iberian minnows (Teleostei, Cyprinidae) evidenced by sequential bandingPolymorphism of major ribosomal gene chromosomal sites (NOR-phenotypes) in the hybridogenetic fish Squalius alburnoides complex (Cyprinidae) assessed through crossing experimentsDNA damage response in imatinib resistant chronic myeloid leukemia K562 cellsDevelopment of imatinib and dasatinib resistance: dynamics of expression of drug transportersABCB1, ABCC1, ABCG2, MVP, and SLC22A1Frequency of C9orf72 hexanucleotide repeat expansion and SOD1 mutations in Portuguese patients with amyotrophic lateral sclerosisSimultaneous production of triploid and haploid eggs by triploid Squalius alburnoides (Teleostei: Cyprinidae)C9orf72 expansion is associated with accelerated decline of respiratory function and decreased survival in amyotrophic lateral sclerosisTransforming growth factor-β plasma levels and its role in amyotrophic lateral sclerosisFamily history of neurodegenerative disorders in patients with amyotrophic lateral sclerosis: population-based case-control studyReliability of phrenic nerve conduction study: In healthy controls and in patients with primary lateral sclerosisInvestigating LGALS3BP/90 K glycoprotein in the cerebrospinal fluid of patients with neurological diseasesCervical muscle weakness is a marker of respiratory dysfunction in amyotrophic lateral sclerosisInterleukin-6 and amyotrophic lateral sclerosisVRK1 variants in two Portuguese unrelated patients with childhood-onset motor neuron diseaseAssessing upper limb function with ALSFRS-R in amyotrophic lateral sclerosis patientsDiaphragmatic CMAP amplitude from phrenic nerve stimulation predicts functional decline in ALSNovel TBK1 LoF variant in a family with upper motor neuron predominant motor neuron diseaseImpact of comorbidities and co-medication on disease onset and progression in a large German ALS patient groupVery late-onset amyotrophic lateral sclerosis in a Portuguese cohort
P50
Q37961937-88AAE2DE-242A-4CBB-BAB4-5EE21FCBB9DDQ38680540-EDFFF012-DE64-4A03-A527-AF766195F29BQ38791448-5B0711D0-6BF7-430E-A0CC-4519FE7F4AD7Q46241488-4C46AC25-336F-4FC5-B72C-CA5FB4D96B7FQ47592485-8A935203-A414-4696-A1A8-7065E050B81DQ47608879-475C7169-3DEF-4FDD-9D8B-7EEE0832C632Q47936401-4D4B228E-E780-4EDD-88DA-9B7A3EB951D4Q54466394-AB261E34-C032-4213-906B-C986A5FA560EQ57393246-7B8BA92F-BCE9-46CE-AA21-B399F50E8B6DQ57774921-F4E53ED1-2C26-41A4-8EDE-73BA72026983Q58392262-A4BEE2B2-88E0-471F-9087-F49D554FE3E5Q58392269-88E74D00-B79E-4073-965C-07878BB634FBQ58392312-EB921DD7-7673-414D-A0D1-8B17E1671775Q58392329-E937B727-A0A5-4943-BAA8-1FAE4FB9BE4EQ60359854-FB822279-C882-466D-98A1-371A14950C5EQ60447894-D93D9B2B-D823-47F4-A18D-B539AFBB4385Q63259086-71D87952-7113-47E2-A63C-6AC8BB955C44Q63259101-AEF800F9-D502-4B3D-866C-7EB050060CD0Q88376684-E1202843-A20A-45D0-AA69-4E0B753762F1Q89836589-2F25A834-81D6-437B-8D15-B0BFE5319558Q90279898-12556AAB-7244-493D-9356-01764D8665D1Q90468358-116F0A36-02D9-4C72-BC37-35A27CDB7B8AQ90714181-2F306E9A-EA70-45EE-B33C-2C2D8B645FB8Q91150583-C1897004-1805-4DC7-84D5-540B0E834D4AQ91224128-4ADF220F-3F5F-4B25-87D9-4CE3C5A17317Q91525336-521E0041-D422-45BE-BD4A-9E5F6A925481Q91589121-B145BBF4-3047-4106-9EC0-9D45CA97FB2AQ91613040-24CB0FD6-C584-4CC7-96B5-98543B11BC68Q91653385-4EBBA375-B6F4-47C0-A931-A3E0ABB997F9Q91716122-B00042AA-224D-4442-B28D-6F990E20291DQ91844708-3C867DE5-F088-4B6A-A54E-40EAB8398E14
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Marta Gromicho
@ast
Marta Gromicho
@en
Marta Gromicho
@es
Marta Gromicho
@sl
type
label
Marta Gromicho
@ast
Marta Gromicho
@en
Marta Gromicho
@es
Marta Gromicho
@sl
prefLabel
Marta Gromicho
@ast
Marta Gromicho
@en
Marta Gromicho
@es
Marta Gromicho
@sl
P108
P1053
I-5658-2013
P106
P1153
6506583274
P21
P31
P3829
P496
0000-0003-2111-4579